Last reviewed · How we verify
Subconjunctival dexamethasone
Subconjunctival dexamethasone is a Small molecule drug developed by Sun Yat-sen University. It is currently in Phase 1 development.
Subconjunctival dexamethasone is a small molecule intervention used to treat conditions such as Cataract, Glaucoma, and Pterygium. It is administered subconjunctivally, which involves injecting the medication under the conjunctiva, a thin membrane covering the white part of the eye.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Subconjunctival dexamethasone |
|---|---|
| Sponsor | Sun Yat-sen University |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Dropless Pars Plana Vitrectomy Study (PHASE4)
- Effectiveness of Periocular Drug Injection in CATaract Surgery (PHASE3)
- Cyclophotocoagulation in Glaucoma (NA)
- A Two Chemoprophylaxis Approaches After Phacoemulsification Surgery (PHASE4)
- Efficacy and Tolerance Comparison Between Subconjunctival Injection of Triamcinolone and Intravitreal Implant of Dexamethasone for the Treatment of Inflammatory Macular Edema (PHASE3)
- Preoperative Bevacizumab Injection in Primary Pterygium in Tunisian Patients (PHASE4)
- Visual Function in Pediatric Patients With Posterior Lens Opacities
- The Use of Bevacizumab as a Modulator of Wound Healing Following Trabeculectomy Surgery (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Subconjunctival dexamethasone CI brief — competitive landscape report
- Subconjunctival dexamethasone updates RSS · CI watch RSS
- Sun Yat-sen University portfolio CI
Frequently asked questions about Subconjunctival dexamethasone
What is Subconjunctival dexamethasone?
Who makes Subconjunctival dexamethasone?
What development phase is Subconjunctival dexamethasone in?
Related
- Manufacturer: Sun Yat-sen University — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing